



JSC Servier has launched EFFIENT® (INN prasugrel) in Russia, an original pharmaceutical product licensed by Daiichi Sankyo Northern Europe GmbH

JSC Servier is pleased to announce the launch of Effient® in Russia from 27th of March 2018. Pharmaceutical product is used for treatment of patients with acute coronary syndrome (ACS), who undergo percutaneous coronary intervention.

Licensing agreement between Servier and Daiichi Sankyo within the territory of Russia was signed in July 2016. Servier is the marketing authorization holder.

Effient® is registered in more than 65 countries worldwide including the United Kingdom, France, Germany, Italy, Spain, Ireland and USA.

Product has Rx status in Russia and is indicated for the prevention of thrombotic disorders (myocardial infarction, stroke, cardiovascular death) in patients with ACS, who undergo percutaneous coronary intervention (PCI) as well as for the prevention of stent thrombosis in patients with ACS.

This partnership gives a great opportunity for Servier to expand its existing drug portfolio for treatment of cardiovascular diseases and to provide patients with modern high-quality treatment in Russia and EAEU countries.

Board Chairman of the Society of Urgent Cardiology Specialists, MD, Professor S.N. Tereshenko commented: «Prasugrel (Effient®) is the 3rd-line agent and represents the most modern generation of thienopyridines, which has more clinically significant antiplatelet effect compared to clopidogrel (2^d-line agent). Due to greater efficacy, prasugrel (Effient®) has a higher risk of bleeding¹. This risk can be significantly reduced in case prasugrel (Effient®) is used for its direct indications: in patients younger than 75 years, with the index of body weight more than 60 kg and without strokes in anamnesis². It is noteworthy that that among patients with diabetes mellitus, the risk of bleeding with prasugrel (Effient®) does not exceed the risk of bleeding with clopidogrel³. Prasugrel (Effient®) is well known in the world and has been used in clinical practice for 10 years and more. According to it, the launch of prasugrel (Effient®) in the Russian market will help to expand the capacity to assist patients with ACS, leading to a higher quality of a specialized medical care”.



About Acute Coronary Syndrome:

ACS includes acute myocardial infarction (MI), MI with / without ST segment elevation, MI diagnosed by enzyme changes, biomarkers, late ECG signs, and unstable stenocardia. Myocardial infarction is the main manifestation of coronary heart disease, which manifests when the arterial lumen narrows due to the growth of an atherosclerotic plaque. The main role in the origin of ACS belongs to intracoronary thrombosis, which provokes the development of occlusion of the artery and the subsequent initiation of cardiovascular complications (including myocardial infarction, stroke).

¹ - TRITON TIMI 38 NEJM publication

² - Wilcox R et al. Curr Med Res Opin 2014;30:2193-205

³ - Wiviott SD et al. Circulation 2008;118(16):1626-1636



About Servier Group:

Servier is an international pharmaceutical company governed by a non-profit foundation with its headquarters in Suresnes, France. With a strong international presence in 148 countries and a turnover of 4,152 billion euros in 2017, Servier employs 21 600 people worldwide. Corporate growth is driven by Servier's constant search for innovation in five areas of excellence: cardiovascular and immune-inflammatory diseases, neuropsychiatric disorders, cancer and diabetes, as well as by its activities in high-quality generic drugs. Being completely independent, the Group reinvests 25% of turnover (excluding generics) in research and development and uses all its profits for development.

Servier is a leader in cardiology, one of its main therapeutic areas of excellence, number 2 in Europe, number 8 worldwide. Servier portfolio of innovative products is being constantly developed in collaboration with partners worldwide.

For more information, please visit www.servier.com

About Servier Russia:

Servier has been active in Russia for 25 years, where it is one of the leading pharmaceutical companies. In 1999, the company established its Russian Center for Therapeutic Research in Moscow. In 2007, a high-tech pharmaceutical plant opened in Russia in full compliance with GMP standards. Today it is a full-scale plant producing original medicines intended for treatment of major non-communicable diseases for Russian citizens. In 2012 Servier became one of the first international companies to start exporting its products produced in Russia to the CIS countries.

For more information, please visit www.servier.ru

About Daiichi Sankyo:

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence around the globe, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people.

In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group's 2025 Vision to become a "Global Pharma Innovator with a Competitive Advantage in Oncology," Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases.

For more information, please visit: www.daiichisankyo.com